Johnson & Johnson and Legend Biotech’s Carvykti shows improved survival in treatment-experienced multiple myeloma patients
As a 2nd line therapy for multiple myeloma, Carvykti can lower the risk of disease progression or death by 59% ...
Tag: car-t